Skip to main content
. 2003 Sep 9;89(6):1013–1021. doi: 10.1038/sj.bjc.6601236

Table 1. Characteristics of the patients for whom information on supportive care (SC) was available, divided by trial and chemotherapy arm.

Study ELVIS trial
MILES trial
GEMVIN3 trial
 
Arm SC alone Vinorelbine Vinorelbine Gemcitabine Vinorelbine+gemcitabine Vinorelbine+gemcitabine CDDP-based chemotherapy All patients
Median age (range) 74 (69–85) 74 (69–85) 73 (64–83) 73 (69–86) 73 (69–84) 63 (37–70) 64 (36–71) 71 (36–86)
Gender                
 Male 80 (89%) 65 (87%) 192 (87%) 179 (83%) 173 (79%) 150 (82%) 153 (85%) 992 (84%)
 Female 10 (11%) 10 (13%) 28 (13%) 37 (17%) 46 (21%) 34 (18%) 28 (15%) 193 (16%)
PS                
 0 17 (19%) 15 (20%) 66 (30%) 64 (30%) 60 (27%) 56 (30%) 55 (30%) 333 (28%)
 1 52 (58%) 41 (55%) 113 (51%) 113 (52%) 120 (55%) 103 (56%) 102 (56%) 644 (54%)
 2 21 (23%) 19 (25%) 41 (19%) 39 (18%) 39 (18%) 25 (14%) 24 (13%) 208 (18%)
                 
No of patients 90 75 220 216 219 184 181 1185